甲状腺癌发生的分子机制及其临床应用
Molecular Mechanism and Clinical Application of Thyroid Cancer
DOI: 10.12677/ACM.2023.13122889, PDF,   
作者: 卡地力艳·如孜：新疆医科大学研究生学院，新疆 乌鲁木齐；张 洁*：新疆维吾尔自治区人民医院内分泌科，新疆 乌鲁木齐
关键词: 甲状腺癌；病理类型；发病机制；靶向治疗；Thyroid Cancer； Pathological Type； Pathogenesis； Targeted Therapy
摘要: 甲状腺癌(thyroid cancer, TC)是甲状腺的恶性肿瘤，是内分泌系统恶性肿瘤中最常见的一种。甲状腺癌影响约1%的人口，近年来发病率不断上升，是发病率上升的少数癌症之一。尽管临床治疗取得了进展，包括手术、放疗、左旋甲状腺素治疗和靶向治疗，因为我们目前对不同类型甲状腺癌的遗传背景的了解还远远不够，仍需进一步探索有前景的最佳分子治疗。本文综述了与甲状腺癌不同病理发病相关的分子机制及其临床相关性。
Abstract: Thyroid cancer (TC) is a malignant tumor of thyroid and the most common malignant tumor of en-docrine system. Thyroid cancer affects about 1% of the population. In recent years, its incidence rate has been rising, and it is one of the few cancers with an increasing incidence rate. Although progress has been made in clinical treatment, including surgery, radiotherapy, levothyroxine treatment and targeted therapy, because our current understanding of the genetic background of different types of thyroid cancer is far from enough, we still need to further explore the best molec-ular therapy with prospects. This article reviews the molecular mechanisms and clinical relevance related to different pathological pathogenesis of thyroid cancer.
文章引用：卡地力艳·如孜, 张洁. 甲状腺癌发生的分子机制及其临床应用[J]. 临床医学进展, 2023, 13(12): 20543-20548. https://doi.org/10.12677/ACM.2023.13122889

参考文献

[1] Seib, C.D. and Sosa, J.A. (2018) Evolving Understanding of the Epidemiology of Thyroid Cancer. Endocrinology and Metabolism Clinics of North America, 48, 23-35. [Google Scholar] [CrossRef] [PubMed]
[2] Luzón-Toro, B., Fernández, R., Villalba-Benito, L., et al. (2019) Influencers on Thyroid Cancer Onset: Molecular Genetic Basis. Genes, 10, 913-941. [Google Scholar] [CrossRef] [PubMed]
[3] Perri, F., Giordano, A., Pisconti, S., et al. (2018) Thy-roid Cancer Management: From a Suspicious Nodule to Targeted Therapy. Anticancer Drugs, 29, 483-490. [Google Scholar] [CrossRef] 
[4] Liu, Q., Pan, L.Z., Hu, M., et al. (2020) Molecular Net-work-Based Identification of Circular RNA-Associated ceRNA Network in Papillary Thyroid Cancer. Pathology and Oncology Research, 26, 1293-1299. [Google Scholar] [CrossRef] [PubMed]
[5] Xu, X. and Jing, J. (2020) Advances on circRNAs Contribute to Carcinogenesis and Progression in Papillary Thyroid Carcinoma. Frontiers in Endocrinology (Lausanne), 11, Article ID: 555243. [Google Scholar] [CrossRef] [PubMed]
[6] Kristensen, L.S., Andersen, M.S., Stagsted, L.V.W., et al. (2019) The Biogenesis, Biology and Characterization of Circular RNAs. Nature Reviews. Genetics, 20, 675-691. [Google Scholar] [CrossRef] [PubMed]
[7] Thomson, D.W. and Dinger, M.E. (2016) Endogenous mi-croRNA Sponges: Evidence and Controversy. Nature Reviews. Genetics, 17, 272-283. [Google Scholar] [CrossRef] [PubMed]
[8] Kari, S., Vasko, V.V., Priya, S., et al. (2019) PKA Activates AMPK through LKB1 Signaling in Follicular Thyroid Cancer. Frontiers in Endocrinology (Lausanne), 10, Article No. 769. [Google Scholar] [CrossRef] [PubMed]
[9] Zhang, Q., Xing, Y., Jiang, S., et al. (2020) Integrated Analysis Identifies DUSP5 as a Novel Prognostic Indicator for Thyroid Follicular Carcinoma. Thoracic Cancer, 11, 336-345. [Google Scholar] [CrossRef] [PubMed]
[10] Pitsava, G., Stratakis, C.A. and Faucz, F.R. (2021) PRKAR1A and Thyroid Tumors. Cancers (Basel), 13, Article No. 3834. [Google Scholar] [CrossRef] [PubMed]
[11] Gambardella, C., Offi, C., Patrone, R., et al. (2019) Calcitonin Nega-tive Medullary Thyroid Carcinoma: A Challenging Diagnosis or a Medical Dilemma? BMC Endocrine Disorders, 19, Article No. 45. [Google Scholar] [CrossRef] [PubMed]
[12] Ceolin, L., Duval, M., Benini, A.F., et al. (2019) Medullary Thy-roid Carcinoma beyond Surgery: Advances, Challenges, and Perspectives. Endocrine-Related Cancer, 26, R499-R518. [Google Scholar] [CrossRef] 
[13] Zheng, X., Rui, S., Wang, X.F., et al. (2021) circPVT1 Regulates Me-dullary Thyroid Cancer Growth and Metastasis by Targeting miR-455-5p to Activate CXCL12/CXCR4 Signaling. Jour-nal of Experimental & Clinical Cancer Research, 40, Article No. 157. [Google Scholar] [CrossRef] [PubMed]
[14] Li, A.Y., McCusker, M.G., Russo, A., et al. (2019) RET Fu-sions in Solid Tumors. Cancer Treatment Reviews, 81, Article ID: 101911. [Google Scholar] [CrossRef] [PubMed]
[15] Chatterjee, S. and Chakravarti, A. (2019) A Gene Regulatory Net-work Explains RET-EDNRB Epistasis in Hirschsprung Disease. Human Molecular Genetics, 28, 3137-3147. [Google Scholar] [CrossRef] [PubMed]
[16] Yue, C., Oner, M., Chiu, C., et al. (2021) RET Regulates Human Medul-lary Thyroid Cancer Cell Proliferation through CDK5 and STAT3 Activation. Biomolecules (Basel, Switzerland), 11, Ar-ticle No. 860. [Google Scholar] [CrossRef] [PubMed]
[17] Gebert, L.F.R. and MacRae, I.J. (2019) Regulation of microRNA Function in Animals. Nature Reviews. Molecular Cell Biology, 20, 21-37. [Google Scholar] [CrossRef] [PubMed]
[18] Han, Y., Liao, Q., Wang, H., et al. (2019) High Expression of Calreticulin Indicates Poor Prognosis and Modulates Cell Migration and Invasion via Activating Stat3 in Nasopharyngeal Carcinoma. Journal of Cancer, 10, 5460-5468. [Google Scholar] [CrossRef] [PubMed]
[19] Tang, J., Luo, Y. and Xiao, L. (2022) USP26 Promotes Anaplastic Thyroid Cancer Progression by Stabilizing TAZ. Cell Death & Disease, 13, Article No. 326. [Google Scholar] [CrossRef] [PubMed]
[20] Yang, J. and Barletta, J.A. (2020) Anaplastic Thyroid Carcinoma. Seminars in Diagnostic Pathology, 5, 248-256. [Google Scholar] [CrossRef] [PubMed]
[21] Abe, I. and Lam, A.K. (2021) Anaplastic Thyroid Carcinoma: Current Issues in Genomics and Therapeutics. Current Oncology Reports, 23, Article No. 31. [Google Scholar] [CrossRef] [PubMed]
[22] Panebianco, F., Nikitski, A.V., Nikiforova, M.N., et al. (2019) Spectrum of TERT Promoter Mutations and Mechanisms of Activation in Thyroid Cancer. Cancer Medicine, 8, 5831-5839. [Google Scholar] [CrossRef] [PubMed]
[23] Jin, J., Shi, Y., Zhang, S., et al. (2020) PIK3CA Mutation and Clinicopathological Features of Colorectal Cancer: A Systematic Review and Meta-Analysis. Acta Oncologica, 59, 66-74. [Google Scholar] [CrossRef] 
[24] Du, X., et al. (2018) ALK-Rearrangement in Non-Small-Cell Lung Cancer (NSCLC). Thoracic Cancer, 9, 423-430. [Google Scholar] [CrossRef] [PubMed]
[25] Vosgha, H., Ariana, A., Smith, R.A., et al. (2018) miR-205 Targets Angiogenesis and EMT Concurrently in Anaplastic Thyroid Carcinoma. Endocrine-Related Cancer, 25, 323-337. [Google Scholar] [CrossRef] 
[26] Hu, J., Yuan, I.J., Mirshahidi, S., et al. (2021) Thyroid Carcinoma: Phenotypic Features, Underlying Biology and Potential Relevance for Targeting Therapy. International Journal of Mo-lecular Sciences, 22, Article No. 1950. [Google Scholar] [CrossRef] [PubMed]
[27] Kim, B.H., et al. (2016) Recent Updates on the Management of Medul-lary Thyroid Carcinoma. Endocrinology and Metabolism (Seoul), 31, 392-399. [Google Scholar] [CrossRef] 

为你推荐